Harms of prescribing NSAIDs to high risk groups estimated to cost NHS £31m over 10 years

Prescribing non-steroidal anti-inflammatory drugs (NSAIDs) to people at high risk of harm from them is estimated to cost the NHS in England around £31 million and cause more than 6,000 lost years of good health over 10 years, finds a study published by The BMJ today.

NSAIDs continue to be a source of avoidable harm and healthcare costs, and more needs to be done to address this, especially in high risk groups, say the researchers.

NSAIDs are used for pain and inflammation and are one of the most widely prescribed groups of medicines in the world, But they are known to increase the risk of gastrointestinal bleeding, heart attacks, stroke, and kidney damage.

Yet despite a range of initiatives to reduce their use, NSAID prescribing is still common in people at high risk of harm due to older age, previous peptic ulcer, heart failure, chronic kidney disease, or who are taking other medications that can increase bleeding risk.

To help inform policy in this area, the researchers set out to estimate levels of patient harm and the costs of NSAID prescribing to high risk groups in the NHS in England over a 10 year period.

The researchers drew on previously published research on prescribing safety in England, which provided a baseline number of people affected by ‘hazardous prescribing events’ in April 2020, based on data from the national roll-out of PINCER (pharmacist-led information technology intervention for medication errors) and prevalence data from 1060 general practices (10,906,453 patients in total).

They identified rates of hazardous prescribing events for oral NSAIDs in five high risk groups: adults aged 65 and over with no gastroprotection; people with a previous peptic ulcer with no gastroprotection; people who concurrently took blood thinning drugs (anticoagulants); people with heart failure; and those with chronic kidney disease.

They then used economic models to estimate the harm associated with each hazardous prescribing event at the patient level, expressed as quality adjusted life years (QALYs) lost – a measure of years lived in good health – and the cost to the NHS in England of managing that harm.

The results show that average QALYs per person (where 1.0 is equivalent to perfect health and 0 is equivalent to being dead) were between 0.01 lower with previous peptic ulcer, to 0.11 lower with chronic kidney disease.

Average costs increased from a non-statistically significant £14 in heart failure to a statistically significant £1,097 in people also taking anticoagulants. 

Rates of hazardous prescribing events per 1,000 patients ranged from 0.11 in people with a previous peptic ulcer, to 1.70 in older adults. 

Nationally, the most common hazardous prescribing event (older adults without gastroprotection) results in 1,929 QALYs lost, costing £2.46 million, while the greatest impact is in people also taking anticoagulants, with 2,143 QALYs lost, costing £25.41 million.

Over 10 years, the five NSAID related hazardous prescribing events led to a total loss of 6,335 QALYs at an estimated cost of £31.43 million to the NHS in England. 

Shorter durations of exposure were associated with lower risk of harms, but at least half of the observed harms occurred in the first 1.5 years of treatment.

These are observational findings, and the researchers point to several limitations around assumed dose, length of exposure, and accounting for all harms, which may have affected their estimates. And the results may not apply to other non-UK settings, they note.

However, they say the types, severity, and probability of NSAID-related harm are likely to be transferable, and further analyses to test the strength of the main findings yielded similar results, suggesting that they withstand scrutiny. 

As such, they conclude: “NSAIDs continue to be a source of avoidable harm and healthcare costs, despite a range of initiatives to reduce their use, especially in populations at high risk .. therefore, a concerted effort should be made to continue to include NSAIDs in patient safety and deprescribing initiatives.”

[Ends]